Trial Profile
A Repeat-Dose, Open-Label, Parallel-Group Study to Assess the Pharmacokinetics of GSK1278863 and Metabolites in Subjects With End Stage Renal Disease Undergoing Peritoneal Dialysis
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 26 Aug 2023
Price :
$35
*
At a glance
- Drugs Daprodustat (Primary)
- Indications Anaemia
- Focus Pharmacokinetics
- Sponsors GlaxoSmithKline; GlaxoSmithKline Research & Development; GSK
- 13 Oct 2017 Status changed from recruiting to completed.
- 05 Jun 2017 Planned End Date changed from 1 Jun 2017 to 16 Aug 2017.
- 05 Jun 2017 Planned primary completion date changed from 1 Apr 2017 to 16 Aug 2017.